Molecular Epidemiology and Mechanisms of High-Level Resistance to Meropenem and Imipenem in Pseudomonas aeruginosa

被引:26
|
作者
Hassuna, Noha Anwar [1 ]
Darwish, Marwa K. [2 ]
Sayed, Mohamed [1 ]
Ibrahem, Reham Ali [3 ]
机构
[1] Menia Univ, Fac Med, Med Microbiol & Immunol Dept, Al Minya, Egypt
[2] Suez Univ, Fac Sci, Biochem Branch, Chem Dept, Suez, Egypt
[3] Menia Univ, Fac Pharm, Microbiol & Immunol Dept, Al Minya, Egypt
来源
关键词
carbapenems; efflux pump; OprD and metallo-beta-lactamases; METALLO-BETA-LACTAMASE; CARBAPENEM-RESISTANCE; EFFLUX PUMPS; EXPRESSION; STRAINS; OPRD; PCR; ASSOCIATION; SYSTEM; IMPACT;
D O I
10.2147/IDR.S233808
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose: Pseudomonas aeruginosa possesses a large number of resistance mechanisms to different antimicrobials with carbapenems being the most powerful in treating resistant P. aeruginosa. Hence, it is imperative to explore different mechanisms of carbapenemsresistance in P. aeruginosa to achieve successful treatment through the design of new drugs acting on this interaction to combat against antimicrobial resistance. Strains and Methods: A total of 634 P. aeruginosa clinical isolates were collected from various patient sources and their MIC levels were measured. Molecular evaluation of carbapenem resistance was assessed by investigating the presence of bla(IMP1), bla(IMP2), bla(VIM1), bla(VIM2), bla(NDM) and b/a NDm genes and the gene expression of the following multidrug efflux pump systems: MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM and its correlation with MIC. Isolates were typed by Random Amplified Polymorphic DNA (RAPD)-typing. Results: Carbapenem resistance was detected in 32 (5%) isolates, which were all imipenem resistant (of which 29 were meropenem resistant). High-level resistance (>= 64mg/mL) to imipenem was found in 27 (84.3%) isolates, and to meropenem in 28 (96.5%) isolates. The carbapenemase bla(VIM-1) was found in 31 isolates, while bla(NDM) was detected in 4 isolates. None of the isolates possessed either bla(VIM-2), bla(IMP-1), bla(IMP-1) or bla(SPM). The majority of the isolates displayed over-expression of MexCD-OprJ (75%) followed by MexXY-OprM efflux pump (62%), while MexAB-OprM and MexEF-OprN efflux pumps were overexpressed in 21.8% and 18.7% of the isolates, respectively, with no down-regulation of oprD in any of the isolates. A strong correlation was found between CDJ efflux pump expression and meropenem, imipenem resistance (r=0.532, 0.654, p<0.001, <0.001) respectively. Four major clusters were detected by RAPD-typing: group 1(10 isolates), group 3 (9 isolates), group 2 (8 isolates) while the fourth group (4) included 4 isolates (12.5% polymorphism). Conclusion: High-level carbapenem resistance reported in this study was allied to multiple mechanisms including carbapenemase production and efflux-pump over-expression. Threatening cross-infection is possible inside the hospital and stringent infection control measures are crucial.
引用
收藏
页码:285 / 293
页数:9
相关论文
共 50 条
  • [1] Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem
    Riera, Elena
    Cabot, Gabriel
    Mulet, Xavier
    Garcia-Castillo, Maria
    del Campo, Rosa
    Juan, Carlos
    Canton, Rafael
    Oliver, Antonio
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (09) : 2022 - 2027
  • [2] Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa
    Rodriguez-Martinez, Jose-Manuel
    Poirel, Laurent
    Nordmann, Patrice
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (11) : 4783 - 4788
  • [3] Mechanisms of Heteroresistance and Resistance to Imipenem in Pseudomonas aeruginosa
    Xu, Ye
    Zheng, Xiangkuo
    Zeng, Weiliang
    Chen, Tao
    Liao, Wenli
    Qian, Jiao
    Lin, Jie
    Zhou, Cui
    Tian, Xuebin
    Cao, Jianming
    Zhou, Tieli
    [J]. INFECTION AND DRUG RESISTANCE, 2020, 13 : 1419 - 1428
  • [4] HIGH-LEVEL QUINOLONE RESISTANCE IN PSEUDOMONAS-AERUGINOSA
    PIDDOCK, LJV
    PANCHAL, S
    INGLIS, TJJ
    HAWKEY, PM
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 (02) : 229 - 231
  • [5] Genomic epidemiology and ceftazidime-avibactam high-level resistance mechanisms of Pseudomonas aeruginosa in China from 2010 to 2022
    Li, Xi
    Zhou, Longjie
    Lei, Tailong
    Zhang, Xiaofan
    Yao, Jiayao
    He, Jintao
    Liu, Haiyang
    Cai, Heng
    Ji, Jingshu
    Zhu, Yiwei
    Tu, Yuexing
    Yu, Yunsong
    Zhou, Hua
    [J]. EMERGING MICROBES & INFECTIONS, 2024, 13 (01)
  • [6] In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa
    Gomis-Font, Maria A.
    Cabot, Gabriel
    Sanchez-Diener, Irina
    Fraile-Ribot, Pablo A.
    Juan, Carlos
    Moya, Bartolome
    Zamorano, Laura
    Oliver, Antonio
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (09) : 2508 - 2515
  • [7] Resistance to imipenem in Pseudomonas aeruginosa
    King, A
    Shannon, K
    Phillips, I
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 (06) : 1037 - 1041
  • [8] Meropenem resistance in Pseudomonas aeruginosa
    Sumita, Y
    Fukasawa, M
    [J]. CHEMOTHERAPY, 1996, 42 (01) : 47 - 56
  • [9] Imipenem resistance in Pseudomonas aeruginosa
    Fille, M
    Bauernfeind, A
    Eberlein, E
    Jungwirth, R
    Schneider, I
    Speer, G
    Dierich, MP
    Allerberger, F
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 1998, 110 (20) : 715 - 720
  • [10] MECHANISMS OF HIGH-LEVEL RESISTANCE TO QUINOLONES IN URINARY-TRACT ISOLATES OF PSEUDOMONAS-AERUGINOSA
    YOSHIDA, T
    MURATANI, T
    IYOBE, S
    MITSUHASHI, S
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (07) : 1466 - 1469